Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more

More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/6a338eaccf4b6a4aa9381eb175a996c437c5b2e7"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about employer coverage of obesity drugs, another Sanofi setback, and more"></iframe>

STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more

More from Health

STAT+: A suspicious denial pattern in Medicare Advantage

STAT+: Novartis doubles down on molecular glue strategy

STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study

STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about employer coverage of obesity drugs, another Sanofi setback, and more

More from Health

STAT+: A suspicious denial pattern in Medicare Advantage

STAT+: Novartis doubles down on molecular glue strategy

STAT+: Enliven Therapeutics&#8217; leukemia drug shows promise in new study

STAT+: &#8216;Synthetic lethality&#8217; could trigger another round of biotech M&#038;A

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more

STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study

STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A